Regeneron's Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentech's Lucentis

     Regeneron's Eylea Now Captures One-Quarter Of Wet AMD Patient Share,
                Surpassing Share Of Roche/Genentech's Lucentis

Eylea's Convenient Dosing Frequency Likely Drives Product Initiation, Although
High Satisfaction Among Prescribers Likely Motivates Continued Use, According
to a New Report from BioTrends Research Group

PR Newswire

EXTON, Penn., Aug. 15, 2013

EXTON, Penn., Aug. 15, 2013 /PRNewswire/ --BioTrends Research Group, one of
the world's leading research and advisory firms for specialized
biopharmaceutical issues, finds that surveyed retinal specialists/general
ophthalmologists now treat 26 percent of their intravitreal pharmaceutically
treated wet age-related macular degeneration (AMD) patients with Regeneron's
Eylea, a significant increase from one year ago. Eylea has been on the market
since November 2011. In fact, patient share for Eylea now surpasses that for
Roche/Genentech's Lucentis (21 percent), which has been available since 2006.
However, off-label use of Roche/Genentech's Avastin continues to dominate the
wet AMD market, largely due to its low cost relative to the other
anti-vascular endothelial growth factor (VEGF) agents and proven efficacy.

According to the TreatmentTrends®: Dry/Wet AMD (US) report, physician
preference for Eylea is likely driven by its convenient twice monthly dosing
frequency, which is supported by the finding that wet AMD patients receive
significantly fewer Eylea injections than Avastin or Lucentis injections
during the first two years of treatment. Data from the report also suggest
that Eylea is moving up in the wet AMD treatment algorithm and is now the most
preferred branded therapy indicated for the treatment of wet AMD, with
Lucentis being the typical third-line treatment option.

"This shift in Eylea use is likely motivated by prescribers' high satisfaction
with the agent and their positive perceptions related to its efficacy," said
BioTrends Research Group Senior Business Insights Analyst Emma Williams, Ph.D.
"These perceptions will contribute to the continued growth of Eylea patient
share over the next six months and will trail only Avastin's patient share."

Report findings also reveal that surveyed physicians rate geographic atrophy
associated with dry AMD as the AMD disease type with the greatest need for new
products, a finding which is not surprising given the high degree of vision
loss suffered by these patients and the paucity of treatment options currently
available for dry AMD. However, even as physicians acknowledge the high unmet
need for dry AMD, few are aware of products in development for dry AMD,
including Otsuka/Acucela's ACU-4429 and MacuCLEAR's MC-1101. Instead,
awareness is higher for surveyed products in development for wet AMD, in
particular Ophthotech's Fovista, Ohr Pharmaceuticals's squalamine and
Allergan's anti-VEGF DARPin. Surveyed physicians perceive these products for
wet AMD as having potential to provide the most value to the treatment of
their AMD patients, largely due to Fovista's synergistic effect when
administered with an anti-VEGF agent, squalamine's eye drop formulation and
anti-VEGF DARPin's novel mechanism of action and duration of action.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please visit BioTrends is a
Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group

Press spacebar to pause and continue. Press esc to stop.